Live antigen carriers as tools for improved anti-tuberculosis vaccines.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Live antigen carriers as tools for improved anti-tuberculosis vaccines.

FEMS Immunol Med Microbiol. 1999 Feb;23(2):165-73. Unique Identifier : AIDSLINE MED/99174532
Hess J; Kaufmann SH; Max-Planck-Institute for Infection Biology, Department of; Immunology, Berlin, Germany. Hess@mpiib-berlin.mpg.de

Abstract: Recombinant (r) Mycobacterium bovis BCG strains have been constructed which secrete biologically active listeriolysin (Hly) fusion protein of Listeria monocytogenes. In human and murine macrophage-like cell lines, intracellular persistence of these r-BCG strains was reduced as compared to the parental BCG strain. By immunogold labelling Hly was detected in membrane structures and within the phagosomal space of macrophages. Hly fusions consistently co-localized with a lysosome-associated membrane glycoprotein (LAMP-1) suggesting that membrane attack conformation of Hly was not altered. Although r-BCG microorganisms apparently did not egress into the cytoplasmic compartment of host cells, they both improved major histocompatibility complex class I presentation of co-phagocytosed soluble ovalbumin as compared with wild-type BCG microbes. These data suggest that Hly secretion endows BCG with an improved capacity to stimulate CD8 T cells. Because CD8 T cells play a major role in protection against tuberculosis such Hly-secreting r-BCG constructs are anti-tuberculosis vaccine candidates. In addition, we report on our r-Salmonella typhimurium expression system combined with the HlyB/HlyD/ TolC export machinery for delivering the prominent mycobacterial antigen Ag85B for immune recognition.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Animal Antigens, Bacterial/GENETICS/IMMUNOLOGY BCG Vaccine/GENETICS/*IMMUNOLOGY Cytotoxins/GENETICS/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Human Salmonella typhimurium/GENETICS Support, Non-U.S. Gov't Tuberculosis/*IMMUNOLOGY/*PREVENTION & CONTROL/THERAPY Vaccines, Synthetic/*IMMUNOLOGY
990730
A9971197

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .